Daratumumab with pomalidomide and dexamethasone for first-relapse multiple myeloma

Prospective, Multicenter, Open and Non-interference Observational Clinical Study of Daratumumab, Pomalidomide and Dexamethasone (Dara-PD) in the Treatment of Patients With First Relapse of Multiple Myeloma

This will follow people with first-relapse multiple myeloma who receive daratumumab plus pomalidomide and dexamethasone to see if they go longer before the next progression than people on other contemporary regimens.

Quick facts

• Study type: Observational
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: The First Hospital of Jilin University (Academic / other)
• Drugs / interventions: daratumumab
• Locations: 1 site (Changchun, Jilin)
• Trial ID: NCT06252792 on ClinicalTrials.gov

What this trial studies

This is a prospective, multicenter, open-label, non-interventional observational study comparing outcomes for patients with first-relapse multiple myeloma treated with daratumumab plus pomalidomide and dexamethasone (Dara‑Pd) versus other regimens used in the same period. The primary outcome is second progression-free survival (PFS2), defined as time from enrollment to disease progression or death. Eligible patients are adults with symptomatic, measurable multiple myeloma at first relapse who previously received a proteasome inhibitor– and immunomodulator‑based (RVD) first-line regimen and achieved at least a partial response. Safety and comparative effectiveness data versus contemporaneous regimens (e.g., Dara‑KPD, VPd, KPd, IPd, Pd) will be collected across participating Chinese centers without assigning treatments.

Who should consider this trial

Good fit: Adults (≥18) with symptomatic, measurable multiple myeloma at first relapse who previously received RVD first-line therapy and achieved at least a partial response are ideal candidates.

Not a fit: Patients with more than one prior relapse, non‑measurable disease, significant contraindications to daratumumab or pomalidomide, or who did not receive RVD as first-line therapy are unlikely to be eligible or benefit from the results.

Why it matters

Potential benefit: If successful, the findings could help doctors choose whether Dara‑Pd leads to longer time to next progression compared with other commonly used regimens at first relapse.

How similar studies have performed: Other randomized and single‑arm trials have shown that adding daratumumab to pomalidomide and dexamethasone can improve outcomes in relapsed multiple myeloma, so this observational comparison builds on existing evidence.

Eligibility criteria

Inclusion Criteria:

Subjects will be enrolled in this study only if they met all of the following inclusion criteria.

1. Age 18 years or older, regardless of gender.
2. Diagnosis of symptomatic multiple myeloma based on the 2014 IMWG diagnostic criteria and the presence of measurable disease
3. First relapse of multiple myeloma;
4. Receiving first-line anti-multiple myeloma therapy;
5. The first-line therapy must be based on proteasome inhibitors and immunomodulators (RVD);
6. Subject must have achieved a response (partial response \[PR\] or better based on investigator's determination of response by the IMWG criteria) to at one prior regimen;
7. Each subject (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.
8. Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. Contraception must begin 4 weeks prior to dosing and continue until at least 3 months after receiving the last dose of the study drug. A woman of childbearing potential must have a negative serum or urine pregnancy tests at screening within 14 days prior to randomization.

Exclusion Criteria:

1. Diagnosis of inactive multiple myeloma, including primary amyloidosis, MGUS (monoclonal gammopathy of undetermined significance) or smoldering myeloma.
2. Relapsed and refractory myeloma：Relapsed and refractory myeloma is defined as disease that is nonresponsive while on salvage therapy, or progresses within 60 days of last therapy in patients who have achieved minimal response (MR) or better at some point previously before then progressing in their disease course；
3. Primary refractory myeloma：Primary refractory myeloma is defined as disease that is nonresponsive in patients who have never achieved a minimal response or better with any therapy；
4. Subject has received daratumumab or pomalidomide previously；
5. Subject has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization (exceptions is malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).；
6. Subjects with uncontrollable psychiatric disorders;
7. Subject is known or suspected of not being able to comply with the study protocol.Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject or that could prevent, limit, or confound the protocol-specified assessments.

Where this trial is running

Changchun, Jilin

• The First Hospital of Jilin University — Changchun, Jilin, China (Recruiting)

Conditions Multiple Myeloma; First Relapse; First relapse; the second progression free survival time